MTOR and prostate carcinoma: It has been revealed that AKT/mTOR over-expressed and PTEN expression was significantly decreased in conditions of proliferative dysregulation and a variety of solid tumors including prostate cancer and gastric cancer (Nicholson and Anderson, 2002[33]; Hartmann et al., 2009[19]; Riquelme et al., 2016[37]).